In the British Journal of Cancer, researchers from South Korea present a dose-escalation study of the drug irinotecan for patients with advanced gastric cancer, and determine the drug's effect on the UGT1A1 genotype. The team administered increasing doses of irinotecan to 43 patients and sequenced DNA isolate from their peripheral blood to determine their UGT1A1 genotypes. The overall response rate was 9.3 percent, and the disease control rate was 62.8 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.